Starzl T E, Porter K A, Andres G, Groth C G, Putnam C W, Penn I, Halgrimson C G, Starkie S J, Brettschneider L
Clin Exp Immunol. 1970 Jun;6(6):803-14.
The course of forty-six consecutive patients were studied for 3½–5 years after renal homotransplantation from related and unrelated donors. Transthoracic thymectomy was performed before transplantation in twenty-four cases; the other twenty-two recipients served as controls. A similar spectrum of donor-recipient lymphocyte antigen compatibility was present in both the test and control series. In both the related and non-related cases, there was no clinical evidence that the patients with thymectomy had either an early or late advantage in terms of survival, reduced drug dosages, or quality of renal function. However, pathologic studies with light and electron microscopy and with immunofluorescence revealed that the homografts in the thymectomized patients had fewer and less severe lesions of the kind that would be expected to limit the functional life time of these organs.
对46例接受亲属和非亲属供体肾脏同种移植的患者进行了3年半至5年的随访研究。24例患者在移植前接受了经胸胸腺切除术；另外22例接受者作为对照。试验组和对照组的供受体淋巴细胞抗原相容性谱相似。在亲属和非亲属病例中，均无临床证据表明接受胸腺切除术的患者在生存、减少药物剂量或肾功能质量方面有早期或晚期优势。然而，光镜、电镜和免疫荧光病理研究表明，胸腺切除患者的同种移植肾中，预期会限制这些器官功能寿命的病变较少且较轻。
